Across TCGA pan-cancer cohorts, BSDC1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BSDC1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BSDC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BSDC1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
LUAD, UCEC, and SKCM are the cancer types where BSDC1 Mutation most reproducibly stratifies survival.